A radioimmunoassay for 6-keto-prostaglandin F1 alpha.

Laurence Demers, D. D. Derck

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We describe a highly specific RIA for blood and urine 6-keto-PGF1 alpha, the principal metabolite of PGI2. The method requires extraction and column chromatography prior to assay and uses a tritium trace for assay monitoring. Dextran-coated charcoal is used to separate bound from free trace. Acceptable standard curve reproducibility over six assays had a mean correlation of 0.991 with a coefficient of variation of 6.61%. Good precision and accuracy data were generated with this assay, and normal human blood levels in 80 control subjects was less than 125 pg/ml. Significant elevations of blood 6-keto-PGF1 alpha were found in a high proportion of cancer patients with various solid tumor malignancies.

Original languageEnglish (US)
Pages (from-to)193-199
Number of pages7
JournalAdvances in prostaglandin and thromboxane research
Volume6
StatePublished - Jan 1 1980

Fingerprint

6-Ketoprostaglandin F1 alpha
Radioimmunoassay
Neoplasms
Tritium
Charcoal
Epoprostenol
Dextrans
Chromatography
Urine
prostaglandin F1

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{89f9d5043938461b8fc4ed45a1ece8e4,
title = "A radioimmunoassay for 6-keto-prostaglandin F1 alpha.",
abstract = "We describe a highly specific RIA for blood and urine 6-keto-PGF1 alpha, the principal metabolite of PGI2. The method requires extraction and column chromatography prior to assay and uses a tritium trace for assay monitoring. Dextran-coated charcoal is used to separate bound from free trace. Acceptable standard curve reproducibility over six assays had a mean correlation of 0.991 with a coefficient of variation of 6.61{\%}. Good precision and accuracy data were generated with this assay, and normal human blood levels in 80 control subjects was less than 125 pg/ml. Significant elevations of blood 6-keto-PGF1 alpha were found in a high proportion of cancer patients with various solid tumor malignancies.",
author = "Laurence Demers and Derck, {D. D.}",
year = "1980",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "193--199",
journal = "Advances in prostaglandin and thromboxane research",
issn = "0361-5952",
publisher = "Raven Press",

}

A radioimmunoassay for 6-keto-prostaglandin F1 alpha. / Demers, Laurence; Derck, D. D.

In: Advances in prostaglandin and thromboxane research, Vol. 6, 01.01.1980, p. 193-199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A radioimmunoassay for 6-keto-prostaglandin F1 alpha.

AU - Demers, Laurence

AU - Derck, D. D.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - We describe a highly specific RIA for blood and urine 6-keto-PGF1 alpha, the principal metabolite of PGI2. The method requires extraction and column chromatography prior to assay and uses a tritium trace for assay monitoring. Dextran-coated charcoal is used to separate bound from free trace. Acceptable standard curve reproducibility over six assays had a mean correlation of 0.991 with a coefficient of variation of 6.61%. Good precision and accuracy data were generated with this assay, and normal human blood levels in 80 control subjects was less than 125 pg/ml. Significant elevations of blood 6-keto-PGF1 alpha were found in a high proportion of cancer patients with various solid tumor malignancies.

AB - We describe a highly specific RIA for blood and urine 6-keto-PGF1 alpha, the principal metabolite of PGI2. The method requires extraction and column chromatography prior to assay and uses a tritium trace for assay monitoring. Dextran-coated charcoal is used to separate bound from free trace. Acceptable standard curve reproducibility over six assays had a mean correlation of 0.991 with a coefficient of variation of 6.61%. Good precision and accuracy data were generated with this assay, and normal human blood levels in 80 control subjects was less than 125 pg/ml. Significant elevations of blood 6-keto-PGF1 alpha were found in a high proportion of cancer patients with various solid tumor malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0018881559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018881559&partnerID=8YFLogxK

M3 - Article

C2 - 6892975

AN - SCOPUS:0018881559

VL - 6

SP - 193

EP - 199

JO - Advances in prostaglandin and thromboxane research

JF - Advances in prostaglandin and thromboxane research

SN - 0361-5952

ER -